Authors: Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouze M, Dvir A, Soussan-Gutman L, Barlesi F, Tarcic G, Edelheit O, Gandara D, Elkabetz Y
Date: July 2017
Journal: Thoracic Oncology12(7):e81-e84
We present the case of a patient with multiple EGFR mutations that highlights tumor heterogeneity leading to a mixed response to osimertinib and emphasizes the complexity of EGFR-driven lung cancer. Subclonal tumor evolution was proved by tissue biopsy, monitored by serial analyses of cell-free circulating tumor DNA (cfDNA) at disease progression, and addressed using EGFR tyrosine kinase inhibitor (TKI) combination therapy.